Gene therapy for cancer through adenovirus vector‑mediated expression of the Ad5 early region gene 1A based on loss of IGF2 imprinting

Pan,Yuqin; He,Bangshun; Lirong,Zhang; Nie,Zhenlin; Chen,Liping; Gu,Ling; Hoffman,Andrew   R.; Wang,Shukui; Hu,Jifan

doi:10.3892/or.2013.2646

Gene therapy for cancer through adenovirus vector‑mediated expression of the Ad5 early region gene 1A based on loss of IGF2 imprinting

Authors:
- Yuqin Pan
- Bangshun He
- Zhang Lirong
- Zhenlin Nie
- Liping Chen
- Ling Gu
- Andrew R. Hoffman
- Shukui Wang
- Jifan Hu
View Affiliations

Affiliations: Central Laboratory of Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu 210012, P.R. China, Department of Medicine, Stanford University Medical School, Palo Alto, CA 94304, USA, VA Palo Alto Health Care System, Palo Alto, CA 94304, USA
Published online on: July 30, 2013 https://doi.org/10.3892/or.2013.2646
Pages: 1814-1822

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Loss of (genomic) imprinting (LOI) of the insulin-like growth factor 2 gene (IGF2) is a common epigenetic abnormality in many human cancers. IGF2 imprinting is regulated by differentially methylated domains (DMD) in the imprinting control region that is located between IGF2 and H19 on human chromosome 11. In the present study, combined expression of adenoviral vectors (Ad-EGFP and Ad-E1A) driven by H19 enhancer-DMD-H19 promoter complex was investigated and their effects on the tumor growth were assessed in vitro and in vivo. When infected with Ad-EGFP, the cancer cell lines with the LOI, such as HRT-18 and HT-29 cells, had the expression of the EGFP protein, whereas three cancer cell lines with the maintenance of imprinting (MOI) (HCT-116, MCF-7 and GES-1) had weak expression of EGFP. Furthermore, the expressed Ad-E1A significantly decreased cell viability and induced cell apoptosis only in HRT-18 and HT-29 cells in vitro, and effectively suppressed tumor development in HRT-18 and HT-29 xenograft in nude mice. It is concluded that this gene therapy vector is effective in the suppression of the growth of human colon cancer cells in vitro and in vivo, and that cancer gene therapy based on loss of IGF2 imprinting may prove to be a novel therapeutic option.

View Figures

View References

1	Rainier S, Johnson LA, Dobry CJ, Ping AJ, Grundy PE and Feinberg AP: Relaxation of imprinted genes in human cancer. Nature. 362:747–749. 1993. View Article : Google Scholar : PubMed/NCBI
2	Feinberg AP: Genomic imprinting and gene activation in cancer. Nat Genet. 4:110–113. 1993. View Article : Google Scholar : PubMed/NCBI
3	Reik W, Constancia M, Dean W, Davies K, Bowden L, Murrell A, Feil R, Walter J and Kelsey G: Igf2 imprinting in development and disease. Int J Dev Biol. 4:145–150. 2000.
4	Arney KL: H19 and Igf2-enhancing the confusion? Trends Genet. 19:17–23. 2003. View Article : Google Scholar : PubMed/NCBI
5	Thorvaldsen JL, Duran KL and Bartolomei MS: Deletion of the H19 differentially methylated domain results in loss of imprinted expression of H19 and Igf2. Genes Dev. 12:3693–3702. 1998. View Article : Google Scholar : PubMed/NCBI
6	Hark AT, Schoenherr CJ, Katz DJ, Ingram RS, Levorse JM and Tilghman SM: CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus. Nature. 405:486–489. 2000. View Article : Google Scholar : PubMed/NCBI
7	Bell AC and Felsenfeld G: Methylation of a CTCF-dependent boundary controls imprinted expression of the Igf2 gene. Nature. 405:482–485. 2000. View Article : Google Scholar : PubMed/NCBI
8	Kanduri C, Pant V, Loukinov D, et al: Functional association of CTCF with the insulator upstream of the H19 gene is parent of origin-specific and methylation-sensitive. Curr Biol. 10:853–856. 2000. View Article : Google Scholar : PubMed/NCBI
9	Ling JQ, Li T, Hu JF, et al: CTCF mediates interchromosomal colocalization between Igf2/H19 and Wsb1/Nf1. Science. 312:269–272. 2006. View Article : Google Scholar : PubMed/NCBI
10	Leighton PA, Saam JR, Ingram RS, Stewart CL and Tilghman SM: An enhancer deletion affects both H19 and Igf2 expression. Genes Dev. 9:2079–2089. 1995. View Article : Google Scholar : PubMed/NCBI
11	Schoenherr CJ, Levorse JM and Tilghman SM: CTCF maintains differential methylation at the Igf2/H19 locus. Nat Genet. 33:66–69. 2003. View Article : Google Scholar : PubMed/NCBI
12	Fedoriw AM, Stein P, Svoboda P, Schultz RM and Bartolomei MS: Transgenic RNAi reveals essential function for CTCF in H19 gene imprinting. Science. 303:238–240. 2004. View Article : Google Scholar : PubMed/NCBI
13	Chen HL, Li T, Qiu XW, et al: Correction of aberrant imprinting of IGF2 in human tumors by nuclear transfer-induced epigenetic reprogramming. EMBO J. 25:5329–5338. 2006. View Article : Google Scholar : PubMed/NCBI
14	Vile RG, Russell SJ and Lemoine NR: Cancer gene therapy: hard lessons and new courses. Gene Ther. 7:2–8. 2000. View Article : Google Scholar : PubMed/NCBI
15	Gómez-Navarro J, Curiel DT and Douglas JT: Gene therapy for cancer. Eur J Cancer. 35:2039–2057. 1999.
16	Robbins PD and Ghivizzani SC: Viral vectors for gene therapy. Pharmacol Ther. 80:35–47. 1998. View Article : Google Scholar : PubMed/NCBI
17	Branton PE, Bayley ST and Graham FL: Transformation by human adenoviruses. Biochim Biophys Acta. 780:67–94. 1985.PubMed/NCBI
18	Radke JR, Siddiqui ZK, Miura TA, Routes JM and Cook JL: E1A oncogene enhancement of caspase-2-mediated mitochondrial injury sensitizes cells to macrophage nitric oxide-induced apoptosis. J Immunol. 180:8272–8279. 2008. View Article : Google Scholar
19	Sánchez-Prieto R, Quintanilla M, Cano A, et al: Carcinoma cell lines become sensitive to DNA-damaging agents by the expression of the adenovirus E1A gene. Oncogene. 13:1083–1092. 1996.PubMed/NCBI
20	Adler V, Yin Z, Fuchs SY, et al: Regulation of JNK signaling by GSTp. EMBO J. 18:1321–1334. 1999. View Article : Google Scholar : PubMed/NCBI
21	Szabó PE and Mann JR: Biallelic expression of imprinted genes in the mouse germ line: implications for erasure, establishment, and mechanisms of genomic imprinting. Genes Dev. 9:1857–1868. 1995.PubMed/NCBI
22	Kaneda A and Feinberg AP: Loss of imprinting of IGF2: a common epigenetic modifier of intestinal tumor risk. Cancer Res. 65:11236–11240. 2005. View Article : Google Scholar : PubMed/NCBI
23	Li T, Hu JF, Qiu X, et al: CTCF regulates allelic expression of Igf2 by orchestrating a promoter-polycomb repressive complex 2 intrachromosomal loop. Mol Cell Biol. 28:6473–6482. 2008. View Article : Google Scholar : PubMed/NCBI
24	Hu JF, Vu TH and Hoffman AR: Promoter-specific modulation of insulin-like growth factor II genomic imprinting by inhibitors of DNA methylation. J Biol Chem. 271:18253–18262. 1996. View Article : Google Scholar : PubMed/NCBI
25	Kurukuti S, Tiwari VK, Tavoosidana G, et al: CTCF binding at the H19 imprinting control region mediates maternally inherited higher-order chromatin conformation to restrict enhancer access to Igf2. Proc Natl Acad Sci USA. 103:10684–10689. 2006. View Article : Google Scholar
26	Yoon YS, Jeong S, Rong Q, Park KY, Chung JH and Pfeifer K: Analysis of the H19ICR insulator. Mol Cell Biol. 27:3499–3510. 2007. View Article : Google Scholar : PubMed/NCBI